References
- D. Hanahan and R. A. Weinberg, Hallmarks of cancer: The next generation, Cell 144(5) 646–674; https://doi.org/10.1016/j.cell.2011.02.013
- R. L. Siegel, K. D. Miller and A. Jemal, Cancer statistics, 2016, CA Cancer J. Clin. 66(1) (2016) 7–30; https://doi.org/10.3322/caac.21332
- M. Vanneman and G. Dranoff, Combining immunotherapy and targeted therapies in cancer treatment, Nat. Rev. Cancer 12(4) (2012) 237–251; https://doi.org/10.1038/nrc3237
- A. Pathak, S. Tanwar, V. Kumar and B. D. Banarjee, Present and future prospect of small molecule & related targeted therapy against human cancer, Vivechan Int. J. Res. 9(1) (2018) 36–49.
- F. A. Fisusi and E. O. Akala, Drug combinations in breast cancer therapy, Pharm. Nanotechnol. 7(1) (2019) 3–23; https://doi.org/10.2174/2211738507666190122111224
- B. B. Mishra and V. K. Tiwari, Natural products: an evolving role in future drug discovery, Eur. J. Med. Chem. 46(10) (2011) 4769–4807; https://doi.org/10.1016/j.ejmech.2011.07.057
- G. M. Cragg and D. J. Newman, Plants as a source of anti-cancer agents, J. Ethnopharmacol. 100(1–2) (2005) 72–79; https://doi.org/10.1016/j.jep.2005.05.011
- F. M. de Man, A. K. L. Goey, R. H. N. van Schaik, R. H. J. Mathijssen and S. Bins, Individualization of irinotecan treatment: A review of pharmacokinetics, pharmacodynamics, and pharmacogenetics, Clin. Pharmacokinet. 57(10) (2018) 1229–1254; https://doi.org/10.1007/s40262-018-0644-7
- A. B. Benson, A. P. Venook, M. M. Al-Hawary, M. A. Arain, Yi-J. Chen, K. K. Ciombor, S. Cohen, H. S. Cooper, D. Deming, L. Farkas, I. Garrido-Laguna, J. L. Grem, A. Gunn, J. R. Hecht, S. Hoffe, J. Hubbard, S. Hunt, K. L. Johung, N. Kirilcuk, S. Krishnamurthi, W. A. Messersmith, J. Meyerhardt, E. D. Miller, M. F. Mulcahy, S. Nurkin, M. J. Overman, A. Parikh, H. Patel, K. Pedersen, L. Saltz, C. Schneider, D. Shibata, J. M. Skibber, C. T. Sofocleous, E. M. Stoffel, E. Stotsky-Himelfarb, C. G. Willett, K. M. Gregory and L. A. Gurski, Colon cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, J. Nat. Compreh. Cancer Network 19(3) (2021) 329–359; https://doi.org/10.6004/jnccn.2021.0012
- A. J. Alonso-Castro, M. L. Villarreal, L. A. Salazar-Olivo, M. Gomez-Sanchez, F. Dominguez and A. Garcia-Carranca, Mexican medicinal plants used for cancer treatment: pharmacological, phyto-chemical and ethnobotanical studies, J. Ethnopharmacol. 133(3) (2011) 945–972; https://doi.org/10.1016/j.jep.2010.11.055
- N. F. Bussa and A. Belayneh, Traditional medicinal plants used to treat cancer, tumors and inflammatory ailments in Harari Region, Eastern Ethiopia, South Afr. J. Bot. 122 (2019) 360–368; https://doi.org/https://doi.org/10.1016/j.sajb.2019.03.025
- T. Teklehaymanot and M. Giday, Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia, J. Ethnobiol. Ethnomed. 3 (2007) Article ID 12 (11 pages); https://doi.org/10.1186/1746-4269-3-12
- T. Teklehaymanot, Ethnobotanical study of knowledge and medicinal plants used by the people in Dek Island in Ethiopia, J. Ethnopharmacol. 124(1) (2009) 69–78; https://doi.org/10.1016/j.jep.2009.04.005
- V. Kuete, B. Krusche, M. Youns, I. Voukeng, A. G. Fankam, S. Tankeo, S. Lacmata and T. Efferth, Cytotoxicity of some Cameroonian spices and selected medicinal plant extracts, J. Ethnopharmacol. 134(3) (2011) 803–812; https://doi.org/10.1016/j.jep.2011.01.035
- F. A. Adem, V. Kuete, A. T. Mbaveng, M. Heydenreich, A. Ndakala, B. Irungu, T. Efferth and A. Yenesew, Cytotoxic benzylbenzofuran derivatives from Dorstenia kameruniana, Fitoterapia 128 (2018) 26–30; https://doi.org/10.1016/j.fitote.2018.04.019
- T. Uchiyama, S. Hara, M. Makino and Y. Fujimoto, seco-Adianane-type triterpenoids from Dorstenia brasiliensis (Moraceae), Phytochemistry 60(8) (2002) 761–764.
- V. Kuete, A. T. Mbaveng, M. Zeino, B. Ngameni, G. D. Kapche, S. F. Kouam, B. T. Ngadjui and T. Efferth, Cytotoxicity of two naturally occurring flavonoids (dorsmanin F and poinsettifolin B) towards multi-factorial drug-resistant cancer cells, Phytomedicine 22(7–8) (2015) 737–743; https://doi.org/10.1016/j.phymed.2015.04.007
- R. Heinke, K. Franke, A. Porzel, L. A. Wessjohann, N. A. Ali and J. Schmidt, Furanocoumarins from Dorstenia foetida, Phytochemistry 72(9) (2011) 929–934; https://doi.org/10.1016/j.phytochem.2011.03.008
- C. A. Schneider, W. S. Rasband and K. W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis, Nature Meth. 9(7) (2012) 671–675; https://doi.org/10.1038/nmeth.2089
- P. Kumar, A. Nagarajan and P. D. Uchil, Analysis of cell viability by the MTT assay, Cold Spring Harbor Protoc. 2018(6) (2018) 469–471; https://doi.org/10.1101/pdb.prot095505
- S. W. Jarantow, E. D. Pisors and M. L. Chiu, Introduction to the use of linear and nonlinear regression analysis in quantitative biological assays, Curr. Prot. 3(6) (2023) e801; https://doi.org/https://doi.org/10.1002/cpz1.801
- I. V. Bijnsdorp, E. Giovannetti and G. J. Peters, Analysis of drug interactions, Meth. Mol. Biol. 731 (2011) 421–434; https://doi.org/10.1007/978-1-61779-080-5_34
- T. C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res. 70(2) (2010) 440–446; https://doi.org/10.1158/0008-5472.Can-09-1947
- K. Franke, A. Porzel, M. Masaoud, G. Adam and J. Schmidt, Furanocoumarins from Dorstenia gigas, Phytochemistry 56(6) (2001) 611–621; https://doi.org/10.1016/s0031-9422(00)00419-2
- B. Ngameni, V. Kuete, I. K. Simo, A. T. Mbaveng, P. K. Awoussong, R. Patnam, R. Roy and B. T. Ngadjui, Antibacterial and antifungal activities of the crude extract and compounds from Dorstenia turbinata (Moraceae), South Afr. J. Bot. 75(2) (2009) 256–261; https://doi.org/https://doi.org/10.1016/j.sajb.2008.11.006
- J. Jamalis, F. S. M. Yusof, S. Chander, R. A. Wahab, P. B. D, M. Sankaranarayanan, F. Almalki and T. B. Hadda, Psoralen derivatives: Recent advances of synthetic strategy and pharmacological properties, Antiinflamm. Antiallergy Agents Med. Chem. 19(3) (2020) 222–239; https://doi.org/10.2174/1871523018666190625170802
- Y. Ren, X. Song, Lu Tan, C. Guo, M. Wang, H. Liu, Z. Cao, Y. Li and C. Peng, A review of the pharmacological properties of psoralen, Front. Pharmacol. 11 (2020) Article ID 571535 (18 pages); https://doi.org/10.3389/fphar.2020.571535
- J. Guinney, R. Dienstmann, X. Wang, A. de Reyniès, A. Schlicker, C. Soneson, L. Marisa, P. Roepman, G. Nyamundanda, P. Angelino, B. M. Bot, J. S. Morris, I. M. Simon, S. Gerster, E. Fessler, F. De Sousa E. Melo, E. Missiaglia, H. Ramay, D. Barras, K. Homicsko, D. Maru, G. C. Manyam, B. Broom, V. Boige, B. Perez-Villamil, T. Laderas, R. Salazar, J. W. Gray, D. Hanahan, J. Tabernero, R. Bernards, S. H. Friend, P. Laurent-Puig, J. P. Medema, A. Sadanandam, L. Wessels, M. Delorenzi, S. Kopetz, L. Vermeulen and S. Tejpar, The consensus molecular subtypes of colorectal cancer, Nature Med. 21(11) (2015) 1350–1356; https://doi.org/10.1038/nm.3967
- R. Dienstmann, L. Vermeulen, J. Guinney, S. Kopetz, S. Tejpar and J. Tabernero, Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer, Nat. Rev. Cancer 17(2) (2017) 79–92; https://doi.org/10.1038/nrc.2016.126
- K. C. G. Berg, P. W. Eide, I. A. Eilertsen, B. Johannessen, J. Bruun, S. A. Danielsen, M. Bjørnslett, L. A. Meza-Zepeda, M. Eknæs, G. E. Lind, O. Myklebost, R. I. Skotheim, A. Sveen and R. A. Lothe, Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies, Mol. Cancer 16(1) (2017) Article ID 116 (16 pages); https://doi.org/10.1186/s12943-017-0691-y
- A. Sveen, J. Bruun, P. W. Eide, I. A. Eilertsen, L. Ramirez, A. Murumagi, M. Arjama, S. A. Danielsen, K. Kryeziu, E. Elez, J. Tabernero, J. Guinney, H. G. Palmer, A. Nesbakken, O. Kallioniemi, R. Dienstmann and R. A. Lothe, Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies, Clin. Cancer Res. 24(4) (2018) 794–806; https://doi.org/10.1158/1078-0432.ccr-17-1234
- A. Okita, S. Takahashi, K. Ouchi, M. Inoue, M. Watanabe, M. Endo, H. Honda, Y. Yamada and C. Ishioka, Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer, Oncotarget 9(27) (2018) 18698–18711; https://doi.org/10.18632/oncotarget.24617